Authors
Latest:
Investigators Observe Differences in Toxicity for Sarcoma Due to DosingGary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
Latest:
Ongoing Challenges With Trials in the Community Oncology SettingBenjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.
Latest:
Gender-Specific AI Model Advances Understanding of Glioblastoma Progression and Treatment ResponseDistinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.
Latest:
Future Directions After AURIGA: Daratumumab and Lenalidomide in MyelomaAshraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Latest:
Adaptation in Oncology Practice Opens the Door to SpecializationDemands by patients, market pressures, and changing delivery models have brought to the fore the urgency to address whether subspecialization is necessary and entirely feasible.
Latest:
Insights on Extranodal Extension in Head and Neck CancersChristina Henson, MD, discussed some of the current imaging guidelines in head and neck cancer, with a focus on extranodal extension.
Latest:
Venetoclax Combination: IDH1 Inhibitor Plus 7+3 Leads to Higher Remission and MRDWith the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates and MRD negativity in IDH1-mutated AML, offering a promising treatment option for these patients.
Latest:
Navigating Unmet Needs in SR/D cGvHDDr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Latest:
Gynecologic Cancer Awareness Month: Progress Makes Cervical Cancer Highly Treatable, Increasingly PreventableFor Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.
Latest:
Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLLNakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.
Latest:
Lean Six Sigma in Oncology: Insights From Waterhouse and MendenhallDavid M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care in Cincinnati, Ohio, has transformed clinical operations and elevated the quality of patient care.
Latest:
How Data Help Physicians Improve Operations and Achieve Health EquityA US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.
Latest:
Behind the Development of the DCISionRT Test in DCISChirag Shah, MD, discusses the challenges in predicting the risk of local recurrence in patients with ductal carcinoma in situ, and what led to the DCISionRT test.
Latest:
Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With AbemaciclibDose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.
Latest:
Clinical Considerations with Axtilimab in R/R GVHDPanelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
Latest:
Axi-Cel Demonstrates Efficacy in Non-Hodgkin Lymphoma, Including DLBCLCaron Jacobson, MD, discusses the survival and response data for axicabtagene ciloleucel from the phase 1/2 ZUMA-1 trial.
Latest:
Available Options for the Treatment of EGFR+ Lung CancerEdward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.
Latest:
IL-10 and CXCL10 in Urine May Predict Response to BCG Therapy in Bladder CancerFelix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.
Latest:
Optimizing Transplant Timing in Acute Lymphoblastic LeukemiaPartow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
Latest:
Novel Treatment Strategies in Endometrial CancerClosing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Latest:
Bladder Cancer Field Leans Towards Patient-Centered CareTracy Rose, MD, discusses the promising outlook of the current bladder cancer space.
Latest:
Exploring Advancements in Higher-Risk MDSDespite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.
Latest:
Pegsitacianine Informs Surgery in Peritoneal CarcinomatosisCurrently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.
Latest:
Nearly 4 Years Later, Pembrolizumab Plus CRT Shows Staying PowerSalma Jabbour, MD, discusses the implications of a 4-year follow-up of the KEYNOTE-799 study of pembrolizumab and chemoradiotherapy in stage III non–small cell lung cancer.
Latest:
Deep Responses in Multiple Myeloma Seen With Bispecific AntibodyJeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.
Latest:
Turning the Tide on Opioid Prescribing PracticesIn 2017 there was a continued increase in opioid-related deaths in the United States, with more than 60,000 lives lost. Most opioid abusers report that their opioids are acquired with their own prescription or a prescription for someone else obtained illegally. Two recent retrospective studies found that in patients undergoing surgery for early non–small cell lung cancer, perioperative opioid use was associated with decreased OS and increased risk of recurrence.
Latest:
Cabazitaxel Advances Later-Line Treatment in Metastatic CRPC SettingDuring a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, discussed the results of cabazitaxel as a later-line treatment for patients with metastatic castration-resistant prostate cancer.
Latest:
Evolving Treatment Landscape: Integrating New Evidence Into Clinical PracticePanelists discuss how recent clinical trial data and emerging therapeutic options are reshaping the treatment paradigm for myelofibrosis, requiring thoughtful integration of new evidence into current clinical practice guidelines.
